JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE) ›› 2021, Vol. 41 ›› Issue (3): 386-390.doi: 10.3969/j.issn.1674-8115.2021.03.018

• Review • Previous Articles     Next Articles

Progress in researches on improving engraftment of hematopoietic stem/progenitor cells of cord blood

Liu-xin NING(), Si-guo HAO()   

  1. Department of Hematology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
  • Received:2020-01-15 Online:2021-03-28 Published:2021-04-06
  • Contact: Si-guo HAO E-mail:nlx2108@163.com;haosiguo@xinhuamed.com.cn
  • Supported by:
    Three-year Action Plan for Clinical Skills and Clinical Innovation in Municipal Hospitals of Shanghai Shenkang Hospital Development Center(16CR1033B)

Abstract:

Cord blood transplantation (CBT) has been widely used in the treatment of hematologic malignancies and non-malignant hematologic diseases both in children and adults. Compared with other sources of hematopoietic stem/progenitor cell (HSPC) transplantation, CBT has a higher rate of engraftment failure and delayed hematopoietic system and immune system recovery, thereby increasing the mortality caused by infection and other transplant-related complications. Therefore, how to promote the engraftment of cord blood HSPC has been a hot spot in CBT for many years. The article reviews the latest advances in the strategies to improve the engraftment of HSPC of cord blood.

Key words: cord blood transplantation (CBT), hematopoietic stem/progenitor cell (HSPC), in vitro expansion, engraftment, homing

CLC Number: